- Advertisement -
HomeCURRENT AFFAIRSBUSINESSUzbekistan syrup deaths Case: UP authority cancels licence of pharmaceutical firm 'Marion...

Uzbekistan syrup deaths Case: UP authority cancels licence of pharmaceutical firm ‘Marion Biotech

Uzbekistan syrup deaths Case: UP authority cancels licence of pharmaceutical firm ‘Marion Biotech

Uzbekistan syrup deaths Case: The Uttar Pradesh authorities canceled the manufacturing licence of Noida-based pharmaceutical company “Marion Biotech” on Wednesday, March 22, in the most recent developments concerning the cough syrup deaths in Uzbekistan. Marion Biotech’s cough medicine Dok-1 has been held responsible for the deaths of 18 children in Uzbekistan.

The government and state drugs authorities in India launched an inquiry in response to the occurrence that took place in December 2022.

The firm’s licence has been suspended since January, at which point a thorough investigation was started. Currently, the Uttar Pradesh Drugs Controlling and Licensing Authority has revoked the company’s licence. According to a government official, the company can no longer produce the syrup, according to PTI.

After inspections at its factory by the national and state drug authorities in the wake of the incident, the company’s production licence was suspended in January.
A “medical product alert” was issued by WHO.

The World Health Organization (WHO) also issued a “medical product alert” on January 12 of this year in reference to two substandard (contaminated) items that were discovered in Uzbekistan and reported to it on December 22, 2022.

Earlier on March 3, the Noida Police detained three Marion Biotech employees from the company’s Sector 67 office, and a FIR was filed against all of them, leading to the issuance of a lookout notice for two of its directors.

Marion Biotech’s drugs were “adulterated”

The investigation had found that samples of Marion Biotech’s drugs were “adulterated” and “not of standard quality,” leading to the filing of the FIR.

22 of the samples were discovered to be “not of standard quality” (adulterated and fake), according to the FIR, after being forwarded to the government’s regional drug testing laboratory in Chandigarh.

The FIR was filed in violation of Indian Penal Code Sections 274 (adulteration of drugs), 275 (selling of adulterated drugs), 276 (sale of drug as a different drug or medical preparation), Section 17 (misbranded drugs), and other related provisions of the 1940 Drugs and Cosmetics Act.

Also Read: BMW CE 04: BMW electric scooter showcased in India, could launch soon as the most expensive electric scooter

Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOKINSTAGRAM, and TWITTER.

Enter Your Email To get daily Newsletter in your inbox

- Advertisement -

Latest Post

Latest News

- Advertisement -